Korean Medication Algorithm for Depressive Disorder: Comparisons with Other Treatment Guidelines

被引:17
|
作者
Wang, Hee Ryung [1 ]
Bahk, Won-Myong [1 ]
Seo, Jeang Seok [2 ]
Woo, Young Sup [1 ]
Park, Young -Min [3 ]
Jeong, Jong-Hyun [4 ]
Kim, Won [5 ,6 ]
Shim, Se-Hoon [7 ]
Lee, Jung Goo [8 ,9 ,10 ]
Jon, Duk-In [11 ]
Min, Kyung Joon [12 ]
机构
[1] Catholic Univ Korea, Dept Psychiat, Coll Med, Seoul, South Korea
[2] Konkuk Univ, Dept Psychiat, Sch Med, Chungju, South Korea
[3] Inje Univ, Coll Med, Dept Psychiat, Ilsan Paik Hosp, Goyang, South Korea
[4] Catholic Univ Korea, St Vincents Hosp, Dept Psychiat, Coll Med, Suwon, South Korea
[5] Inje Univ, Sch Med, Dept Psychiat, Seoul Paik Hosp, Seoul, South Korea
[6] Inje Univ, Stress Res Inst, Seoul, South Korea
[7] Soonchunhyang Univ, Dept Psychiat, Coll Med, Cheonan Hosp, Cheonan, South Korea
[8] Inje Univ, Dept Psychiat, Coll Med, Haeundae Paik Hosp, Busan, South Korea
[9] Inje Univ, Palk Inst Clin Res, Busan, South Korea
[10] Inje Univ, Dept Hlth Sci & Technol, Grad Sch, Busan, South Korea
[11] Hallym Univ, Sacred Heart Hosp, Dept Psychiat, Coll Med, Anyang, South Korea
[12] Chung Ang Univ, Dept Psychiat, Coll Med, Seoul, South Korea
关键词
Depressive disorder; Expert consensus; Guideline; KMAP DD 2017; Therapy; PSYCHIATRY WFSBP GUIDELINES; 2016 CLINICAL GUIDELINES; BIOLOGICAL TREATMENT; CANADIAN NETWORK; WORLD FEDERATION; MOOD; MANAGEMENT; SOCIETIES; ADULTS; LEVOMILNACIPRAN;
D O I
10.9758/cpn.2017.15.3.199
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
In this review, we compared recommendations from the Korean Medication Algorithm Project for Depressive Disorder 2017 (KMAP DD 2017) to other global treatment guidelines for depression. Six global treatment guidelines were reviewed; among the six, 4 were evidence based guidelines, 1 was an expert consensus based guideline, and 1 was an amalgamation of both evidence and expert consensus based recommendations. The recommendations in the KMAP DD 2017 were generally similar to those in other global treatment guidelines, although there were some differences between the guidelines. The KMAP DD 2017 appeared to reflect current changes in the psychopharmacology of depression quite well, like other recently published evidence based guidelines. As an expert consensus based guideline, the KMAP DD 2017 had some limitations. However, considering there are situations in which clinical evidence cannot be drawn from planned clinical trials, the KMAP DD 2017 may be,helpful for Korean psychiatrists making decisions in the clinical settings by complementing previously published evidence based guidelines.
引用
收藏
页码:199 / 209
页数:11
相关论文
共 50 条
  • [31] A Primary Care Focus on the Treatment of Patients With Major Depressive Disorder
    Weihs, Karen
    Wert, Jonathan M.
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2011, 342 (04) : 324 - 330
  • [32] Korean Medication Algorithm for Schizophrenia 2019, Second Revision: Treatment of Psychotic Symptoms
    Lee, Jung Suk
    Yun, Je-Yeon
    Kang, Shi Hyun
    Lee, Seung Jae
    Choi, Joon-Ho
    Nam, Beomwoo
    Lee, Seung-Hwan
    Chung, Young-Chul
    Kim, Chan-Hyung
    CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2020, 18 (03) : 386 - 394
  • [33] Program of algorithm for pharmacological treatment of major depressive disorder in China: Benefits or not?
    Zhu, Yuncheng
    Wang, Fang
    Wang, Fan
    Liu, Hongmei
    Guo, Xiaoyun
    Wang, Zuowei
    He, Ruoqiao
    Wu, Xiaohui
    Cao, Lan
    Wu, Zhiguo
    Peng, Daihui
    Fang, Yiru
    HELIYON, 2023, 9 (11)
  • [34] A Primary Care Focus on the Diagnosis and Treatment of Major Depressive Disorder in Adults
    Halaris, Angelos
    JOURNAL OF PSYCHIATRIC PRACTICE, 2011, 17 (05) : 340 - 350
  • [35] Different dosage regimens of zuranolone in the treatment of major depressive disorder: A meta-analysis of randomized controlled trials
    Lian, Jinrong
    Lin, Zhimin
    Li, Xiang
    Chen, Gang
    Wu, Depei
    JOURNAL OF AFFECTIVE DISORDERS, 2024, 354 : 206 - 215
  • [36] Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement
    Dodd, Seetal
    Mitchell, Philip B.
    Bauer, Michael
    Yatham, Lakshmi
    Young, Allan H.
    Kennedy, Sidney H.
    Williams, Lana
    Suppes, Trisha
    Lopez Jaramillo, Carlos
    Trivedi, Madhukar H.
    Fava, Maurizio
    Rush, A. John
    McIntyre, Roger S.
    Thase, Michael E.
    Lam, Raymond W.
    Severus, Emanuel
    Kasper, Siegfried
    Berk, Michael
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2018, 19 (05) : 330 - 348
  • [37] Updates and Trends in the Treatment of Major Depressive Disorder
    Papakostas, George I.
    Ionescu, Dawn F.
    JOURNAL OF CLINICAL PSYCHIATRY, 2014, 75 (12) : 1419 - 1421
  • [38] Impact of serotonergic medication on interoception in major depressive disorder
    Burrows, Kaiping
    DeVille, Danielle C.
    Cosgrove, Kelly T.
    Kuplicki, Rayus T.
    Paulus, Martin P.
    Aupperle, Robin S.
    Khalsa, Sahib L.
    Stewart, Jennifer
    BIOLOGICAL PSYCHOLOGY, 2022, 169
  • [39] The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: The Clinical Guidelines
    Fountoulakis, Konstantinos N.
    Grunze, Heinz
    Vieta, Eduard
    Young, Allan
    Yatham, Lakshmi
    Blier, Pierre
    Kasper, Siegfried
    Moeller, Hans Jurgen
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2017, 20 (02) : 180 - 195
  • [40] Pharmacological treatment of a depressive episode and recurrent depressive disorder - guidelines of the Polish Psychiatric Association and the National Consultant for Adult Psychiatry
    Samochowiec, Jerzy
    Dudek, Dominika
    Kucharska-Mazur, Jolanta
    Murawiec, Slawomir
    Rymaszewska, Joanna
    Cubiala, Wieslaw Jerzy
    Heitzman, Janusz
    Szulc, Agata
    Bala, Malgorzata
    Galecki, Piotr
    PSYCHIATRIA POLSKA, 2021, 55 (02) : 235 - 259